JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 59 filers reported holding JOUNCE THERAPEUTICS INC in Q1 2017. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $60,000 | -96.0% | 12,200 | -95.0% | 0.00% | -94.3% |
| Q1 2019 | $1,514,000 | +60.6% | 244,300 | -12.7% | 0.07% | +7.7% |
| Q4 2018 | $943,000 | -44.2% | 279,900 | +7.7% | 0.06% | -33.0% |
| Q3 2018 | $1,689,000 | +2.2% | 259,857 | +20.5% | 0.10% | 0.0% |
| Q2 2018 | $1,652,000 | +22.5% | 215,700 | +257.1% | 0.10% | +12.8% |
| Q1 2018 | $1,349,000 | -29.7% | 60,400 | -59.9% | 0.09% | -16.5% |
| Q4 2017 | $1,918,000 | -24.1% | 150,500 | -7.2% | 0.10% | -23.7% |
| Q3 2017 | $2,527,000 | +43.8% | 162,200 | +29.4% | 0.14% | +25.0% |
| Q2 2017 | $1,757,000 | +30.6% | 125,300 | +104.7% | 0.11% | +27.1% |
| Q1 2017 | $1,345,000 | – | 61,200 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 9,200,349 | $64,402,000 | 44.86% |
| TRV GP III, LLC | 3,048,780 | $21,342,000 | 1.83% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 406,665 | $2,847,000 | 1.65% |
| Sofinnova Investments, Inc. | 925,280 | $6,477,000 | 0.39% |
| Omega Fund Management, LLC | 334,965 | $2,345,000 | 0.35% |
| Yorktown Management & Research Co Inc | 49,200 | $344,000 | 0.31% |
| Woodline Partners LP | 940,902 | $6,586,000 | 0.18% |
| HUSSMAN STRATEGIC ADVISORS, INC. | 51,000 | $357,000 | 0.09% |
| HORIZON FINANCIAL SERVICES, LLC | 12,005 | $84,000 | 0.08% |
| Gyon Technologies Capital Management, LP | 26,893 | $188,000 | 0.06% |